高危前列腺癌中雄激素剥夺治疗时长与外照射放疗联合或不联合近距离放疗增效的相互作用:3个队列的患者水平数据分析
该队列研究分析3项研究共3410例高危前列腺癌患者,发现放疗类型与ADT时长存在显著交互作用。自然三次样条分析显示,单纯EBRT的最佳DMFS最低ADT时长阈值为26.3个月,EBRT+BT为12个月。RADAR试验中EBRT+BT延长ADT与DMFS改善相关(HR 0.56),而单纯EBRT无显著改善;DART中28个月ADT较18个月改善DMFS(HR 0.37)。
要点
- 高危前列腺癌中放疗类型与ADT时长存在显著交互作用。
- 单纯EBRT的最佳DMFS最低ADT时长阈值为26.3个月。
- EBRT+BT的最佳DMFS最低ADT时长阈值为12个月。
核心结论
- 这些队列研究结果表明,单纯高剂量EBRT的最佳最低ADT时长超过18个月;而EBRT+BT为18个月或可能更短。
- 需要额外研究以确定更精确的最低时长。
研究设计与样本
- 队列研究,纳入3个队列:多中心回顾性研究(2000-2013)、RADAR随机临床试验的事后分析(2003-2007)、RADAR与DART随机临床试验的跨试验比较(2005-2010)。
- 共分析3410例高危前列腺癌男性(平均年龄68岁,范围62-74岁;未收集种族和民族信息)。
- 回顾性队列中1827例接受EBRT、1108例接受EBRT+BT;RADAR中181例接受EBRT、203例接受EBRT+BT;DART中91例接受EBRT。
- 研究于2020年10月15日至2021年7月1日进行,数据分析于2021年1月5日至6月15日进行。
主要发现
- 发现治疗类型(EBRT vs EBRT+BT)与ADT时长(按<6、6至<18、≥18个月分组)之间存在显著交互作用。
- 自然三次样条分析确定单纯EBRT对DMFS最佳效果的最低时长阈值为26.3个月(95% CI,25.4-36.0个月),EBRT+BT为12个月(95% CI,4.9-36.0个月)。
- RADAR中,仅接受EBRT的患者延长ADT与DMFS无显著改善相关(HR 1.01;95% CI,0.65-1.57);而接受EBRT+BT的患者延长ADT与DMFS改善相关(DMFS HR 0.56;95% CI,0.36-0.87;P=0.01)。
- DART中仅接受EBRT的患者,28个月ADT较18个月与DMFS改善相关(RADAR HR 0.37;95% CI,0.17-0.80;P=0.01)。
关键数值与推荐
- 单纯EBRT的最佳DMFS最低ADT时长阈值为26.3个月(95% CI,25.4-36.0个月)。
- EBRT+BT的最佳DMFS最低ADT时长阈值为12个月(95% CI,4.9-36.0个月)。
- RADAR中EBRT+BT延长ADT的DMFS HR为0.56(95% CI,0.36-0.87;P=0.01)。
- DART中28个月ADT较18个月的DMFS HR为0.37(95% CI,0.17-0.80;P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要额外研究以确定更精确的最低时长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Radiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and the required minimum duration of ADT is uncertain. OBJECTIVE: To determine the specific ADT duration threshold that provides a distant metastasis-free survival (DMFS) benefit in patients with high-risk prostate cancer receiving external beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT). DESIGN, SETTINGS, AND PARTICIPANTS: This was a cohort study of 3 cohorts assembled from a multicenter retrospective study (2000-2013); a post hoc analysis of the Randomized Androgen Deprivation and Radiotherapy 03/04 (RADAR; 2003-2007) randomized clinical trial (RCT); and a cross-trial comparison of the RADAR vs the Deprivación Androgénica y Radio Terapía (Androgen Deprivation and Radiation Therapy; DART) 01/05 RCT (2005-2010). In all, the study analyzed 1827 patients treated with EBRT and 1108 patients treated with EBRT+BT from the retrospective cohort; 181 treated with EBRT and 203 with EBRT+BT from RADAR; and 91 patients treated with EBRT from DART. The study was conducted from October 15, 2020, to July 1, 2021, and the data analyses, from January 5 to June 15, 2021. EXPOSURES: High-dose EBRT or EBRT+BT for an ADT duration determined by patient-physician choice (retrospective) or by randomization (RCTs). MAIN OUTCOMES AND MEASURES: The primary outcome was DMFS; secondary outcome was overall survival (OS). Natural cubic spline analysis identified minimum thresholds (months). RESULTS: This cohort study of 3 studies totaling 3410 men (mean age [SD], 68 [62-74] years; race and ethnicity not collected) with high-risk prostate cancer found a significant interaction between the treatment type (EBRT vs EBRT+BT) and ADT duration (binned to <6, 6 to <18, and ≥18 months). Natural cubic spline analysis identified minimum duration thresholds of 26.3 months (95% CI, 25.4-36.0 months) for EBRT and 12 months (95% CI, 4.9-36.0 months) for EBRT+BT for optimal effect on DMFS. In RADAR, the prolongation of ADT for patients receiving only EBRT was not associated with significant improvements in DMFS (hazard ratio [HR], 1.01; 95% CI, 0.65-1.57); however, for patients receiving EBRT+BT, a longer duration was associated with improved DMFS (DMFS HR, 0.56; 95% CI, 0.36-0.87; P = .01). For patients receiving EBRT alone (DART), 28 months of ADT was associated with improved DMFS compared with 18 months (RADAR HR, 0.37; 95% CI, 0.17-0.80; P = .01). CONCLUSIONS AND RELEVANCE: These cohort study findings suggest that the optimal minimum ADT duration for treatment with high-dose EBRT alone is more than 18 months; and for EBRT+BT, it is 18 months or possibly less. Additional studies are needed to determine more precise minimum durations.
引用
- Kishan AU, Steigler A, Denham JW, et al. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022. PMID: 35050303. doi:10.1001/jamaoncol.2021.6871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。